Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://themonetpaintings.org
Are you over 18 and want to see adult content?
A complete backup of https://alexadm63.ru
Are you over 18 and want to see adult content?
A complete backup of https://informativoangolano.com
Are you over 18 and want to see adult content?
A complete backup of https://roadstershop.com
Are you over 18 and want to see adult content?
A complete backup of https://mikulas.sk
Are you over 18 and want to see adult content?
A complete backup of https://giftfromwithin.org
Are you over 18 and want to see adult content?
A complete backup of https://astraclub.ru
Are you over 18 and want to see adult content?
A complete backup of https://parkuj24.pl
Are you over 18 and want to see adult content?
A complete backup of https://whatsgaming.net
Are you over 18 and want to see adult content?
A complete backup of https://dutchgrammar.com
Are you over 18 and want to see adult content?
A complete backup of https://jetaudio.com
Are you over 18 and want to see adult content?
A complete backup of https://smoton.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of stardustcolors.com
Are you over 18 and want to see adult content?
A complete backup of buypillsonline.space
Are you over 18 and want to see adult content?
A complete backup of flattenthecurve.com
Are you over 18 and want to see adult content?
A complete backup of becker-polsterei.de
Are you over 18 and want to see adult content?
A complete backup of torontopubliclibrary.ca
Are you over 18 and want to see adult content?
A complete backup of storefrontthemes.com
Are you over 18 and want to see adult content?
A complete backup of studsandspikes.com
Are you over 18 and want to see adult content?
A complete backup of onlinelampenwinkel.nl
Are you over 18 and want to see adult content?
Text
ANTIBODY DISCOVERY
xCella Biosciences is now part of Ligand Pharmaceuticals. xPloration enables cutting-edge antibody discovery from B cells. TEAM | XCELLA BIOSCIENCES K. Dane Wittrup, PhD. Co-founder, C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT NEWS | XCELLA BIOSCIENCES September 10, 2020. Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions of xCella Biosciences and TaurusBiosciences.
PIPELINE | XCELLA BIOSCIENCES XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors. XC-201 has greater specificity to tumors compared to other integrin-binding agents. XC-201 is peptide-Fc fusion: a “mAb-lite.”. Extensive data elucidating mechanism ofaction.
TECHNOLOGY | XCELLA BIOSCIENCES TM. xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype and cellular functions at the single cell level, millions of cells at a time. xPloration finds rare antibodies others can’t. Our B cell screening workflow is optimized for functional measurements of CONTACT | XCELLA BIOSCIENCES Contact. 1440 O’Brien Drive, Suite D. Menlo Park, CA 94025. Thanksfor submitting!
ANTIBODY DISCOVERY
xCella Biosciences is now part of Ligand Pharmaceuticals. xPloration enables cutting-edge antibody discovery from B cells. TEAM | XCELLA BIOSCIENCES K. Dane Wittrup, PhD. Co-founder, C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT NEWS | XCELLA BIOSCIENCES September 10, 2020. Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions of xCella Biosciences and TaurusBiosciences.
PIPELINE | XCELLA BIOSCIENCES XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors. XC-201 has greater specificity to tumors compared to other integrin-binding agents. XC-201 is peptide-Fc fusion: a “mAb-lite.”. Extensive data elucidating mechanism ofaction.
TECHNOLOGY | XCELLA BIOSCIENCES TM. xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype and cellular functions at the single cell level, millions of cells at a time. xPloration finds rare antibodies others can’t. Our B cell screening workflow is optimized for functional measurements of CONTACT | XCELLA BIOSCIENCES Contact. 1440 O’Brien Drive, Suite D. Menlo Park, CA 94025. Thanksfor submitting!
ANTIBODY DISCOVERY
xCella Biosciences is now part of Ligand Pharmaceuticals. xPloration enables cutting-edge antibody discovery from B cells. TEAM | XCELLA BIOSCIENCES K. Dane Wittrup, PhD. Co-founder, C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT NEWS | XCELLA BIOSCIENCES September 10, 2020. Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions of xCella Biosciences and TaurusBiosciences.
PIPELINE | XCELLA BIOSCIENCES XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors. XC-201 has greater specificity to tumors compared to other integrin-binding agents. XC-201 is peptide-Fc fusion: a “mAb-lite.”. Extensive data elucidating mechanism ofaction.
TECHNOLOGY | XCELLA BIOSCIENCES TM. xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype and cellular functions at the single cell level, millions of cells at a time. xPloration finds rare antibodies others can’t. Our B cell screening workflow is optimized for functional measurements of CONTACT | XCELLA BIOSCIENCES Contact. 1440 O’Brien Drive, Suite D. Menlo Park, CA 94025. Thanksfor submitting!
ANTIBODY DISCOVERY
xCella Biosciences is now part of Ligand Pharmaceuticals. xPloration enables cutting-edge antibody discovery from B cells. TEAM | XCELLA BIOSCIENCES K. Dane Wittrup, PhD. Co-founder, C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT PIPELINE | XCELLA BIOSCIENCES XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors. XC-201 has greater specificity to tumors compared to other integrin-binding agents. XC-201 is peptide-Fc fusion: a “mAb-lite.”. Extensive data elucidating mechanism ofaction.
NEWS | XCELLA BIOSCIENCES September 10, 2020. Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions of xCella Biosciences and TaurusBiosciences.
TECHNOLOGY | XCELLA BIOSCIENCES TM. xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype and cellular functions at the single cell level, millions of cells at a time. xPloration finds rare antibodies others can’t. Our B cell screening workflow is optimized for functional measurements of CONTACT | XCELLA BIOSCIENCES Contact. 1440 O’Brien Drive, Suite D. Menlo Park, CA 94025. Thanksfor submitting!
ANTIBODY DISCOVERY
xCella Biosciences is now part of Ligand Pharmaceuticals. xPloration enables cutting-edge antibody discovery from B cells. TEAM | XCELLA BIOSCIENCES K. Dane Wittrup, PhD. Co-founder, C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT PIPELINE | XCELLA BIOSCIENCES XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors. XC-201 has greater specificity to tumors compared to other integrin-binding agents. XC-201 is peptide-Fc fusion: a “mAb-lite.”. Extensive data elucidating mechanism ofaction.
NEWS | XCELLA BIOSCIENCES September 10, 2020. Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions of xCella Biosciences and TaurusBiosciences.
TECHNOLOGY | XCELLA BIOSCIENCES TM. xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype and cellular functions at the single cell level, millions of cells at a time. xPloration finds rare antibodies others can’t. Our B cell screening workflow is optimized for functional measurements of CONTACT | XCELLA BIOSCIENCES Contact. 1440 O’Brien Drive, Suite D. Menlo Park, CA 94025. Thanksfor submitting!
ANTIBODY DISCOVERY
xCella Biosciences is now part of Ligand Pharmaceuticals. xPloration enables cutting-edge antibody discovery from B cells. TEAM | XCELLA BIOSCIENCES K. Dane Wittrup, PhD. Co-founder, C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT PIPELINE | XCELLA BIOSCIENCES XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors. XC-201 has greater specificity to tumors compared to other integrin-binding agents. XC-201 is peptide-Fc fusion: a “mAb-lite.”. Extensive data elucidating mechanism ofaction.
NEWS | XCELLA BIOSCIENCES September 10, 2020. Ligand Expands OmniAb® Antibody Discovery Platform Through The Acquisitions of xCella Biosciences and TaurusBiosciences.
TECHNOLOGY | XCELLA BIOSCIENCES TM. xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype and cellular functions at the single cell level, millions of cells at a time. xPloration finds rare antibodies others can’t. Our B cell screening workflow is optimized for functional measurements of CONTACT | XCELLA BIOSCIENCES Contact. 1440 O’Brien Drive, Suite D. Menlo Park, CA 94025. Thanksfor submitting!
PIONEERING PROTEINS TO CONQUER CANCER Developing protein therapeutics to transform patient outcomes with disruptive technology.Learn More
OUR MISSION
xCella is developing best-in-class protein therapeutics as game-changing cancer treatments. Our proprietary xEmplar human antibody library and disruptive xPloration screening technology, combined with our team’s deep expertise in protein engineering and cancer biology, are enabling rapid discovery and development of next-generation therapies for cancer patients. We are building a pipeline of protein therapeutics against emerging oncology targets, including XC-201, a unique clinic ready asset that directs T cell mediated immunotherapy to a broad range of tumors.OUR TECHNOLOGIES
Innovative technologies paired with world-class talent accelerate discovery of efficacious antibodies. Explore Technologies Phone: (650) 461 - 4503 Email: info@xcellabio.com
1490 O’Brien Drive, Suite C Menlo Park, CA 94025*
HOME
*
PIPELINE
*
TECHNOLOGY
*
TEAM
*
NEWS
*
CONTACT
*
More
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0